AtaGenix

Hot search： CD47 │ IL6 │ PD-L1 │ CTLA-4 │ TIGIT
Current Site： Product Center / Antibody Drug Analogues / Adalimumab

Adalimumab

  • 1
  • 2
ATAD00093
-
+
futures
Inquiry
  • Product Details
  • Bioactivity
  • Chemistry
  • How to order
  • Instructions
Catalog No.icon
ATAD00093
INN (International Nonproprietary Name)icon
Adalimumab
Purityicon
>95%
SDS-PAGE imageicon
    Concentrationicon
    1.98mg/ml
    Formulationicon
    PBS buffer PH7.4
    Sourceicon
    CHO cells
    Endotoxin levelicon
    Please contact with the lab for this information.
    Noteicon
    For research use only .
    Descriptionicon
    Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor 2, 3. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA 1. This drug is frequently known as Humira. It is produced by recombinant DNA technology using a mammalian cell expression system. This drug is available in a prefilled syringe form and convenient pen form for subcutaneous self-administered doses 1. A new biosimilar to adalimumab, named adalimumab-adaz, was approved by the FDA on October 31, 2018. This biosimilar is known as Hyrimoz, and is a trademark of Novartis AG 9.
    Bioactivityicon
      Alternative namesicon
      D2E7
      Specificity target name;speciesicon
      TNFSF2/TNF-alpha/TNFA[Homo sapiens]
      Activity in vitroicon
      Adalimumab (anti-TNF-alpha) blocks the interaction of TNF with the p55 and p75 cell surface TNF receptors, thereby neutralising the activity of this cytokine. Through its anti-TNF actions, adalimumab reduces concentrations of matrix metalloproteases (MMP-1 and -3) and other markers of cartilage and synovium turnover, reduces of matrix metalloproteases (MMP-1 and -3) and other markers of cartilage and synovium turnover, and reduces concentrations of acute phase reactants of inflammation (C-reactive protein [CRP] and erythrocyte sedimentation rate [ESR]) and serum cytokines (IL-1β mRNA, IL-1 receptor antagonist, IL-6).
      Speciesicon
      Homo sapiens
      Receptor identificationicon
      IgG1-kappa
      MVicon
      148000.00 Da
      CASicon
      331731-18-1
      Storageicon
      Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
      Store at +4°C short term (1-2 weeks).
      Store at -20 °C 12 months.
      Store at -80°C long term.

      Guarantee and Disclaimer:

      After receiving the product, if finds that the product is mismatched, damaged or missing components, please keep the original package and submit the objection to the company by mail within seven working days. Failure to file an objection within the time limit is considered qualified.

      When the buyer keeps the product, it should be kept in accordance with the storage conditions shown in the product label and the manual. If the product quality is caused by improper storage, it will not be guaranteed.

      When the buyer tests the product, they should be submitted by the beginning of use when found the quality issue, rather than when the product was used or used up, in order to prepare our products for recycling and confirm the quality of the products. If it is the quality problem, our company is responsible for exchange or return. In the event of a claim, our company will compensate the discretion within the scope of the product price limit and will not accept any part of the value of the product itself. Since the date of receipt, the product has not been reflected for more than three months and should not be returned.

      The products provided by our company are for research use only and should not be used for clinical diagnosis or treatment. If a unit or individual changes the use of our products without authorization, we will not bear any responsibility.

      AtaGenix
      Copyright © 2024 Lawyer Theme All Rights Reserved
      Site map | Contact us | Join us